# Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency

> **NCT03636438** · — · ACTIVE_NOT_RECRUITING · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 11 (actual)

## Conditions studied

- Ornithine Transcarbamylase (OTC) Deficiency

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT03636438
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-30
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636438, "Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03636438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*